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Abstract 007 – Table 1. Raw KOOS scores (non-normalized) were used for purposes of statistical analysis
KOOS Subscale Anakinra Treatment Placebo Treatment
Result Mean (SD) Mean (SD) Mean Change (SD) P value Result Mean (SD) Mean (SD) Mean Change (SD) P value
1st timepoint 2nd timepoint 1st timepoint 2nd timepoint
Pain 0> 4 16.7 (7.26) 12.8 (4.4) –3.8 (3.4) 0.043 0 = 4 15.4 (5.4) 12.6 (2.07) –0.6 (2.6) NS
ADL 0> 4 23.0 (14.4) 12.5 (7.1) –10.5 (7.7) 0.028 0 = 4 21.8 (7.3) 20.4 (3.0) –1.4 (8.6) NS
Total 0> 4 85.0 (31.2) 64.7 (25.8) –20.3 (6.7) 0.028 0 = 4 81.2 (16.5) 75.8 (6.2) –5.4 (16.5) NS
QOL 0 > 4 12.8 (4.3) 11.7 (3.9) –1.2 (1.3) 0.084 0 = 4 13.4 (1.8) 12.6 (2.2) –0.8 (1.9) NS
Other Symptoms 0 > 4 13.5 (5.9) 12.0 (7.1) –1.5 (2.1) 0.102 0 > 4 15.4 (5.4) 12.6 (5.3) –2.8 (2.6) 0.080
Sports Function 0 > 4 19 (1.3) 15.7 (4.9) –3.3 (3.7) 0.102 0 = 14 17.4 (3.7) 17.6 (2.4) 0.2 (3.6) NS
ADL 4 > 14 12.5 (7.1) 7.5 (6.2) –5 (4.24) 0.066 4 = 14 20.4 (3.0) 21.4 (7.2) 1 (7.9) NS
Total 4 > 14 64.7 (25.8) 48.3 (28.2) –15 (11.5) 0.066 4 = 14 75.8 (6.2) 77.4 (14.4) 1.6 (13.7) NS
Pain 4 > 14 12.8 (4.4) 9.5 (6.0) –3.0 (2.9) 0.109 4 = 14 12.6 (2.1) 12.8 (4.0) 0.2 (4.8) NS
QOL 4 > 14 11.7 (3.9) 10.3 (4.9) –1.25 (1.0) 0.102 4 < 14 12.6 (2.2) 13.2 (1.92) 0.6 (0.5) 0.083
Sports Function 4 > 14 15.7 (4.9) 12.8 (6.9) –5.0 (4.2) 0.102 4 = 14 17.6 (2.4) 17.4 (3.2) –0.2 (3.0) NS
For purposes of interpretation, 0 > 4 means score at Day 0 was greater than at Day 4, decline in severity over time.
Pain = KOOS pain; ADL = KOOS activities of daily living; QOL = KOOS quality of life subscale; Total = combination of 5 subscales: Pain, ADL and QOL and Other Symptoms and Function in
Sports and Recreation. P value by Wilcoxon rank sum test.
immunoassay (Corgenix; intra- and inter-assay CVs were 2% and 3%
respectively).
Functional Outcomes: The standardized KOOS questionnaire was obtained at
baseline (0), 4 days, 14 days, and 28 days or the day of surgery.
Statistical Analysis: The Wilcoxon rank sum test was used to evaluate the
change in KOOS from baseline to follow-up within a treatment group.
Two-tailed t-test was used to compare the change scores (pre-post synovial
ﬂuid concentrations) between placebo and drug treated groups.
Results: As shown in the table, the Anakinra group had substantially
greater improvement (∼1-3 s.d.) in key outcomes whereas the placebo
group had much less improvement (∼1/4 of s.d. on most outcomes).
Statistically signiﬁcant improvements in KOOS pain (p=0.04) and function
(activities of daily living, p=0.03), and total KOOS (p=0.03) were observed
in response to IL1-Ra, but not placebo. In the anakinra treated group this
corresponded to reductions in Pain of 23%, improvement in Activities of
Daily Living of 46%, and improvement in total KOOS of 24%; in contrast, the
placebo group changed only 4%, 6% and 7% for these outcomes respectively.
There were no adverse reactions in either the anakinra or saline placebo
treated groups.
Synovial ﬂuid IL-1α, IL-1β, and IL-1Ra concentrations exceeded serum
concentrations. IL-1α increased in all the placebo treated patients whereas
it decreased in 4 of 5 of the anakinra treated patients (p=0.05). Although
IL-1 and IL-1Ra declined dramatically over time post injury, there was no
signiﬁcant difference based on treatment. Serum HA decreased in all the
anakinra treated patients (n=6 pairs) from Time 1 to Time 2 (p=0.03) while
the change in the placebo treated patients was not signiﬁcant.
Conclusions: IL-1Ra decreased pain and improved function in our random-
ized pilot trial of acute knee injury. The decreases in serum HA and synovial
ﬂuid IL-1α in the IL-1Ra treated patients are consistent with a decrease in
synovial inﬂammation in acute knee injury in response to IL-1Ra therapy.
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Purpose: Magnetic resonance imaging (MRI)-detected subchondral bone
marrow lesions (BML) are frequently seen in osteoarthritis (OA) of the knee
depicting acute and chronic changes in this tissue. They have been shown
to predict cartilage loss and to correlate with pain. However, the literature
remains contradictory about the latter. Furthermore, we lack knowledge
about treatment effects on BML. The aim of this study was to assess, in a
multicentre randomized double-blind phase III clinical trial evaluating the
effect of licofelone vis-à-vis naproxen on knee OA, the presence of and
change in BML over time and their relationship to cartilage volume loss,
meniscal extrusion, and pain.
Methods: Knee OA patients were selected from the dataset of a recently
published randomized controlled trial [1]. One hundred and sixty-one
patients completed the study according to protocol. MRI was performed
at baseline, 6, 12, and 24 months to assess BML score and cartilage
volume changes over time. Pain levels were assessed using the WOMAC
questionnaire.
Results: Both treatment groups showed increased BML scores compared to
baseline in the global knee (both treatments combined: 0.71±1.85 [mean
±SD], p<0.0001, 24 months) and in all subregions except for the medial tib-
ial plateau where the BML score in the licofelone group remained stable at
12 (-0.01±0.37) and 24 months (-0.01±0.65) vis-à-vis an ongoing increase
in the naproxen group (0.15±0.58, p=0.04; 0.21±0.74, p=0.06, respectively).
In multivariate regression analysis, licofelone treatment predicted reduc-
tion in BML score in the medial tibial plateau (β estimate=-0.27, p=0.02) and
severe meniscal extrusion predicted progression (β estimate=0.26, p=0.03).
BML scores at baseline statistically correlated with cartilage volume (me-
dial, r=-0.24, p=0.002; lateral, r=-0.28, p=0.0003; femoropatellar, r=-0.28,
p=0.0003). In the global and medial compartments, BML score increases
correlated with cartilage loss at 12 months (r=-0.18, p=0.03; r=-0.19, p=0.02,
respectively). No correlation was found between BML and WOMAC pain
scores with the exception of an inverse correlation in the femoropatellar
compartment at 6 (r=-0.22, p=0.006) and 12 months (r=-0.24, p=0.002).
Conclusions: BML scores were found to increase over time, likely reﬂect-
ing an accumulation of chronic changes in subchondral bone tissue. The
correlation between BML and cartilage volume at baseline underlines a
close relationship between them. The reduction in BML might be due to
the unique action of licofelone not only on cyclooxygenases but also on
lipoxygenase. In contrast to previous reports, no positive relationship was
found between BML score (baseline or changes over time) and pain.
Reference
[1] Raynauld JP et al. Ann Rheum Dis 2009;68:938-47.
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Purpose: Bone marrow edema-like lesions (BMLs), which histologically
represent bone damage, are predictors of cartilage loss and pain in knee
osteoarthritis (OA) and represent potential treatment targets. Loss of carti-
lage as part of OA may actually remove a tissue protecting underlying bone,
increasing loading and possibly damage to bone, leading to BMLs. The aim
of this study was to assess the association of prevalent cartilage damage
and cartilage loss over time with incident BMLs in the same subregion of
the knee.
Methods: The Multicenter Osteoarthritis (MOST) Study is a NIH-funded
observational study of individuals who have or are at risk for knee OA.
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Abstract 009 – Table 1. Associations assessed at the medial tibiofemoral compartment
Incident BMLs (30-month) in subregions Crude OR (95% CI) Adjusted OR* (95% CI)
Absence (score = 0) Presence (score ≥ 1)
Normal cartilage morphology at baseline (grades 0 & 1) 3920 (68.2%) 111 (1.9%) 1.0 (reference) 1.0 (reference)
Cartilage damage at baseline (grade ≥ 2) 1526 (26.5%) 196 (3.4%) 4.2 (3.2, 5.4)** 3.5 (2.6, 4.6)**
No cartilage loss between BL and 30-month FU 5128 (89.1%) 197 (3.4%) 1.0 (reference) 1.0 (reference)
Incident (grade 0 at BL and grade ≥ 2 at FU) cartilage loss between BL and 30-month FU 170 (3%) 52 (0.9%) 7.1 (4.9, 10.3)** 7.1 (4.8, 10.5)**
Any cartilage loss between BL and 30-month FU 148 (2.6%) 58 (1%) 8.6 (5.9, 12.4)** 7.0 (4.7, 10.4)**
CI: conﬁdence intervals. * Adjusted for age, gender, BMI, knee alignment, meniscal damage, and meniscal extrusion. **Statistically signiﬁcant deﬁned as p<0.05.
Abstract 009 – Table 2. Associations assessed at the lateral tibiofemoral compartment
Incident BMLs (30-month) in subregions Crude OR (95% CI) Adjusted OR* (95% CI)
Absence (score = 0) Presence (score ≥ 1)
Normal cartilage morphology at baseline (grades 0 & 1) 4916 (80.3%) 60 (1%) 1.0 (reference) 1.0 (reference)
Cartilage damage at baseline (grade ≥ 2) 1080 (17.6%) 67 (1.1%) 4.6 (3.1, 7.0)** 3.4 (2.2, 5.2)**
No cartilage loss between BL and 30-month FU 5759 (94.1%) 88 (1.4%) 1.0 (reference) 1.0 (reference)
Incident (grade 0 at BL and grade ≥ 2 at FU) cartilage loss between BL and 30-month FU 138 (2.3%) 15 (0.3%) 5.7 (3.0, 10.9)** 4.3 (2.3, 8.3)**
Any cartilage loss between BL and 30-month FU 99 (1.6%) 24 (0.4%) 14.6 (8.4, 25.5)** 8.9 (4.8, 16.4)**
CI: conﬁdence intervals. *Adjusted for age, gender, BMI, knee alignment, meniscal damage, and meniscal extrusion. **Statistically signiﬁcant deﬁned as p<0.05.
All subjects with available baseline (BL) and 30-months follow-up (FU)
MRIs were included. MRI was performed on a 1.0T extremity system,
including sagittal and axial proton density fat-suppressed and coronal STIR
sequences. BL and FU MRIs were read using the semiquantitative WORMS
system by two musculoskeletal radiologists. Tibiofemoral compartments
were divided in 10 subregions. Cartilage morphology was scored from 0 to
6. BMLs were scored from 0 to 3. BL cartilage damage was deﬁned as grade
≥2. Subregions of knees showing cartilage loss overtime were divided into
two groups: incident (grades 0 at BL and ≥2 at FU) and progression (BL
cartilage damage with an increased grade at FU by at least 0.5). Incident
BMLs were deﬁned as grades 0 at BL and ≥1 at FU. Subregions with BL
BMLs were excluded. BL cartilage damage and cartilage loss over time
were considered predictors of incident BMLs (outcome), and the absence
of both BL cartilage damage and cartilage loss over time were considered
the reference group. We assessed the association of BL cartilage damage
and cartilage loss over time with incident BMLs in the same subregion
using logistic regression with generalized estimated equations to account
for correlations among the subregions within a knee (using one knee per
person). Adjustments for potential confounders were performed.
Results: 642 knees (1 knee per person, 5753 medial and 6123 lateral
subregions, respectively) were included (women 60.4%, mean age 61.9±7.6,
mean BMI 30.3±4.8). Medially, BL cartilage damage, incident cartilage loss
and progression of cartilage loss were signiﬁcantly associated with incident
BMLs, with adjusted odds ratios (ORs) of 3.5 [95% CI 2.6, 4.6], 7.1 [95%
CI 4.8, 10.5], and 7.0 [95% CI 4.7, 10.4] respectively (Table 1). Laterally,
the same predictors were signiﬁcantly associated with incident BMLs, with
adjusted ORs of 3.4 [95% CI 2.2, 5.3], 4.3 [95% CI 2.3, 8.3], and 8.9 [95% CI
4.8, 16.4] respectively (Table 2).
Conclusions: Prevalent cartilage damage and cartilage loss strongly predict
incident BMLs in the same subregion, supporting the close interrelation of
the osteochondral unit in progression of knee OA. If cartilage damage were
targeted in management of knee OA, it might prevent the development of
BMLs and the associated knee pain.
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IS FOLLISTATIN-LIKE 3 OR FSTL3 NECESSARY FOR JOINT HEALTH?
B. Poulet, J. Mcneil, A.A. Pitsillides
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Purpose: Osteoarthritis (OA) is a debilitating disease in which loss of
joint integrity is manifest as degradation of articular cartilage (AC) and
commonly osteophyte formation, synovial changes, and meniscus and liga-
ment pathologies. Despite this, the cellular and molecular processes of OA
remain elusive. Therefore, identiﬁcation of novel factors that precipitate
or confer protection against OA is very valuable. TGF-b and TGF-b related
proteins are already identiﬁed as key players, yet the role of follistatin-like
3 (FSTL-3), a natural inhibitor of TGF-b family members has not, however,
been explored. Our aim was to examine whether mice deﬁcient in FSTL-3
showed modiﬁcation in joint integrity resembling OA.
Methods: Knee joints from male FSTL-3 deﬁcient mice (FSTL3-KO and
heterogygotes, Hets) and litter-mate WT mice at 18-months (aged), and
younger, were examined. Multiple sections from regular intervals across
entire joints were stained with Toluidine blue and scored for AC lesions
(grade 0-6, normal - exposed bone), osteophyte maturity (0, none to 3,
fully mature) and any abnormal pathological features within the knee joint
noted.
Results: Expectedly, only very mild AC lesions were observed in aged
WT joints (maximum grade=1.75; mean grade=0.81). In contrast, aged
FSTL3 KO mice showed extremely severe AC lesions (maximum=5.33;
mean=4.2) with many joints exhibiting subchondral bone exposure. FSTL3
Hets showed intermediate levels of AC lesion severity (maximum=3;
mean=1.88). Partial growth plate closure was observed in both FSTL3 KO
and Hets. As expected, aged WT mice never showed premature growth
plate closure, osteophyte formation or changes in synovial, meniscus or
ligament integrity. Aged FSTL3 KO mice also showed synovial activation
and ﬁbrosis, and fully mature osteophytes (to grade 3) across all joint
compartments. Hets showed less marked synovial inﬁltration and ﬁbrosis,
and osteophytes were less pronounced and restricted in distribution. FSTL3
KO mice also showed disturbed meniscal structure by local osteophytes
and chondrogenesis/ossiﬁcation of ligaments. Examination of joints from a
few younger, 8-week old FSTL3 KO or Het mice showed no obvious changes
in joint structure.
Conclusions: Our data suggest that FSTL3 is required to maintain AC
integrity and joint health, and that overt OA-like changes emerge with age
in its absence. Our studies also reveal FSTL3 gene dose-dependency in OA
development. Such sensitivity to FSTL3 has not previously been observed
for other characteristic phenotypes in these mice, indicating a heightened
dependence on FSTL3 in protecting against OA. We are currently inves-
tigating the molecular mechanisms of FSTL3-mediated protection against
spontaneous OA and also conﬁrming its reliance upon ageing and the role
of gender and mechanical loading. Our ﬁndings, for the ﬁrst time, identify a
role for follistatin-like 3 in protecting against OA and pinpoint its regulation
as a new target for therapeutic intervention.
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Purpose: Leptin is an apidokine recently linked to inﬂammation and
arthritis and leptin has been proposed to be a metabolic factor connecting
obesity and osteoarthritis (OA). In the present study, the association of
leptin to proinﬂammatory cytokine interleukin-6 (IL-6) and matrix metal-
loproteinases (MMPs) in synovial ﬂuid from OA patients was assessed, and
further, the effects of leptin on the production of IL-6, MMPs and other
inﬂammatory factors in human OA cartilage were investigated.
